Wyrwicz, Lucjan

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study